Results 101 to 110 of about 13,549 (163)

Cardiotoxicity induced by multiple myeloma therapies: mechanistic convergence across proteasome inhibitors, CAR-T, and bispecific antibodies. [PDF]

Blood Cancer J
Chatrathi AR, Patel K, Saini N, Palaskas NL.   +3 more
europepmc   +1 more source

Early deep response to cilta-cel as 2nd CAR T-Cell therapy after CELMoD-based bridging for advanced multiple myeloma. [PDF]

Ann Hematol
Niklas H, Bold A, Völkl S, Lang N, Truger M, Wendelin K, Strifler S, Gärtner J, Knop S.   +8 more
europepmc   +1 more source

Proteasome Inhibitor-Induced Cytotoxic Mechanisms in Canine Pulmonary Adenocarcinoma Cell Lines. [PDF]

Vet Comp Oncol
Chijiwa A, Inanaga S, Osaki T, Igase M, Mizuno T.   +4 more
europepmc   +1 more source

Carfilzomib plus induction chemotherapy for children with relapsed or refractory acute lymphoblastic leukemia. [PDF]

Blood Adv
Locatelli F, Karakukcu M, Huynh V, González-Martínez B, Lins MM, Lu MY, Sulis ML, Pauly M, Morris C, Braunlin M, Talpes M, Gore L.   +11 more
europepmc   +1 more source

Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients. [PDF]

Blood Cancer J
van de Donk NWCJ, Schjesvold F, van der Holt B, Minnema MC, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Bringhen S, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M, Gay F, Sonneveld P, Musto P.   +27 more
europepmc   +1 more source

Cardiovascular disease and amyloidosis in phase III multiple myeloma trials: a systematic review of eligibility, screening and event reporting. [PDF]

Open Heart
Henriques Peck O, McCoubrey A, Snowden JA, Wechalekar A, Travers J, Lees JS, Petrie MC, Lang NN.   +7 more
europepmc   +1 more source

The 19S proteasome as a therapeutic target in hematologic malignancies. [PDF]

Front Cell Dev Biol
Olivas IM, Gonzalez-Henry MA, Darvishi S, Esparza EM, Eiring AM.   +4 more
europepmc   +1 more source

Validation and Exploratory Refinement of the HFA-ICOS Score for Cardiovascular Risk in Proteasome Inhibitor-Treated Multiple Myeloma: Single-Center Retrospective Study. [PDF]

Cancers (Basel)
Pons-Fuster E, Riquelme-Perez A, Shumbar V, González-Ponce CM, Fernandez-Avila JJ, Ramón-Martínez A, Moreno-Belmonte MJ, Cabañas-Perianes V, Pascual-Figal D, Diaz-Carrasco MS, Caro-Martínez C.   +10 more
europepmc   +1 more source

Relapsed/refractory multiple myeloma with extramedullary plasmacytomas successfully rechallenged with humanized B-cell maturation antigen-directed chimeric antigen receptor T-cell immunotherapy in an advanced disease stage: A case report. [PDF]

Exp Ther Med
Zhang R, Cheng L, Liu J, Zhang L, Zhuang J.   +4 more
europepmc   +1 more source

Automated and personalized glioblastoma tumor organoid drug screening platform exposes sensitivity to proteasome and HDAC inhibitors. [PDF]

NPJ Precis Oncol
Jungwirth G, Paul A, Wöllner A, Warta R, Cao J, Fermi V, Jassowicz L, Dao Trong P, von Deimling A, Debus J, Krieg S, Unterberg A, Abdollahi A, Herold-Mende C.   +13 more
europepmc   +1 more source